Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inflammatory Bowel Disease Increases Risk of Type 2 Diabetes in a Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Shift From Adalimumab Originator to Biosimilars in Denmark

    Research output: Contribution to journalLetterpeer-review

View graph of relations

Background: Long-term data on real life use of infliximab (IFX) for inflammatory bowel disease (IBD) are lacking. We studied prescription patterns during the first 16 years following marketing authorization.

Methods: In a population-based cohort from the North Denmark Region, all IBD patients exposed to IFX during 1999 to 2014 were identified.

Results: A total of 623 patients (210 with ulcerative colitis [UC] and 413 with Crohn's disease [CD]) were exposed to IFX. In patients with UC, age at first exposure decreased by 10 months per calendar year (P < 0.05) during the study period. In patients with CD, disease duration at time of first IFX exposure decreased by 7 months per calendar year (P < 0.001). From 2005-2009 to 2010-2014, the proportion of IFX-exposed patients with pancolitis (40% vs 24%, P = 0.04) and the proportion of patients with extensive CD (P = 0.002) decreased. The mean time to discontinuation of IFX remained stable in patients with CD during the study period (2.5-3.0 years) and increased from 0.34 years (2005-2009) to 1.11 years (2010-2015) in patients with UC (P = 0.04).

Conclusion: During the first 16 years postmarketing, age at first exposure to IFX decreased in patients with UC, whereas disease duration at time of first exposure decreased in patients with CD. Also, a significant change toward less extensive disease in both UC and CD patients exposed to IFX was observed. Treatment duration in patients with UC increased during the study period, but did not reach the more constant and longer duration of treatment observed in patients with CD.

Original languageEnglish
JournalInflammatory Bowel Diseases
Volume24
Issue number2
Pages (from-to)433-439
Number of pages7
ISSN1078-0998
DOIs
Publication statusPublished - 18 Jan 2018

    Research areas

  • Journal Article

ID: 52659863